MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » Synthes settles; doc, hospital cleared in Norian XR bone cement suit

Synthes settles; doc, hospital cleared in Norian XR bone cement suit

August 8, 2016 By Fink Densford Leave a Comment

Share

DePuy SynthesJohnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes last week reportedly settled with plaintiffs shortly before a Washington state court jury cleared Dr. Jens Chapman and the University of Washington’s Harborview Medical Center in a case filed by the families of a patient who died on the operating table minutes after injection with DePuy Synthes’ Norian XR bone cement.

The 12-member jury deliberated for more than 3 days, but returned a 10-2 decision that the patient’s death in 2007 was not due to negligence on the part of her surgeon or the hospital, according to The Courtroom View Network.

Synthes was initially a defendant in the case, which began in late June, but the company settled with the plaintiffs “shortly before attorneys delivered their closing arguments,” according to CVN.

The victim’s family was seeking $6 million, with 5% of the responsibility in the death falling on Synthes. The jury did find that Dr. Chapman failed to warn the patient about Norian’s risk, but said that even a clearer warning wouldn’t have kept a “reasonable person” from consenting to use in a back surgery.

The trial is the 1st in a group of civil lawsuits being filed by families of patients who died after being injected with Norian XR bone cement.

At least 5 patients died during otherwise routine operations after the Norian cement was used off-label in their spine surgeries. The bone cement was initially developed by a company called Norian, which Synthes bought in 1999 for about $50 million. Synthes, in turn, was acquired by J&J for $21.3 billion in 2012.

The FDA approved Norian XR for use in arm bones and portions of the skull, but in 2007 required Synthes to put a warning label on the product about its contra-indication for spine surgeries. Lawsuits filed by the families of the patients who died allege that Synthes knew as early as 2002 that Norian XR was unsafe for use in the spine due to its propensity to form clots in the bloodstream, according to Courtroom View Network. Pigs injected with the cement died within minutes and in vitro tests with human blood showed quick clotting the in the compound’s presence, according to court filings cited by the legal news service.

Synthes paid paid $22.5 million in fines and was forced to sell off the Norian subsidiary to settle federal criminal charges that it ran an off-label promotion scheme for the Norian XR cement. Four Synthes executives – Michael Huggins, Thomas Higgins, John Walsh and Richard Bohner – were sentenced to prison terms after pleading guilty to misdemeanor charges over the scheme

In 2012, the families of 2 of the patients who died sued Synthes and the 4 former executives for wrongful death and elder abuse; the family of a 3rd patient filed a lawsuit later that year (1 of those cases later settled in mediation, CVN reported).

In 2013 the families of 2 more patients brought suit against Synthes, Norian, Dr. Jens Chapman and the University of Washington. The families of Reba Golden, who died in 2007, and Joan Bryant, who died in 2009, claim that neither knew about the FDA warning over using Norian in spine procedures. The trial in their case is due to begin June 27 in Seattle’s King County Superior Court.

Johnson & Johnson paid more than $21 billion for Synthes in 2012 . Kensey Nash (NSDQ:KNSY), which paid $22 million for the Norian product line, was later bought up by Dutch firm Royal DSMfor $360 million in 2012.

Filed Under: Legal News, Orthopedics, Spinal Tagged With: depuysynthes, johnsonandjohnson

In case you missed it

  • Here’s how a new Abbott device is making a difference among neonatal infants
  • Conformis: Yale study shows customized knee implants save money
  • Intuitive Surgical wins FDA clearance for robotic-assisted lung biopsy system
  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
  • Phillips-Medisize is expanding in Wisconsin
  • NuVasive wins FDA, CE Mark for Precice internal bone transport system
  • Cash-strapped Aradigm declares bankruptcy
  • ReWalk Robotics files for exoskeleton suit clearance
  • Hancock Jaffe launches first-in-human VenoValve study
  • Medtronic shares rise on FY2019 Q3 earnings beat
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020
  • Medtronic wins FDA’s breakthrough status for closed-loop insulin system
  • India CDSCO adds new medical devices to regulated list
  • Judge sends ‘brain fingerprinting company’ and would-be distributor to arbitration
  • FDA gives massive Medtronic recall Class I designation
  • Affluent Medical touts results of endovascular aneurysm repair study

RSS From Medical Design & Outsourcing

  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
    Medtronic officials continue to hone their arguments for how the company’s capnography and oximetry systems could reduce potentially deadly opioid-induced respiratory compromise. The medical device giant on Feb. 17 announced preliminary results of its Prodigy study, in which the company’s Microstream and Nellcor monitoring technology provided continuous capnography and oximetry for 1,496 patients across 16 sites in the U.S.,… […]
  • Phillips-Medisize is expanding in Wisconsin
    Phillips-Medisize, a Molex company, has broken ground on a new manufacturing facility in Hudson, Wis., on the eastern end of the Minneapolis-St. Paul metro area. The 34-acre location at the St. Croix Meadows development will support at least 230,000 square feet of manufacturing space for FDA-regulated medical device products, Phillips-Medisize announced yesterday. After construction is complete… […]
  • ReWalk Robotics files for exoskeleton suit clearance
      ReWalk Robotics (NSDQ:RWLK) said it has applied to FDA for 510(k) clearance of its ReStore exoskeleton suit for gait training during stroke rehabilitation. The Yokneam, Israel-based company designed its exo-suit to provide coordinated plantarflexion and dorsiflexion assistance to a patient’s foot and ankle. It recently won insurer reimbursement from Cigna and completed a clinical… […]
  • FDA proposes faster post-inspection feedback
    FDA has issued draft guidance providing for more timely nonbinding feedback following medtech facility inspections to advise whether the companies’ proposed corrective actions appear adequate to the agency. The draft guidance proposes a process by which companies can request nonbinding feedback on certain kinds of observations issued on a Form 483. It outlines a standardized method… […]
  • India CDSCO adds new medical devices to regulated list
    By Stewart Eisenhart, Emergo Group India’s Central Drugs Standard Control Organization (CDSCO) continues expanding oversight to more types of medical devices, now planning to require registration for eight additional device types starting April 1, 2020. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s… […]
  • Empowering Medical Innovation
    From faster medical device development to life-saving surgical planning models, see how full-color, multi-material 3D printing opens up broad possibilities for medical innovation. In this new E-book you’ll learn how the Stratasys J750 can: Produce superior medical models for surgical planning and training Foster better medical devices through faster ideation and prototyping Enable advanced training… […]
  • Affluent Medical touts results of endovascular aneurysm repair study
    Medtech startup Affluent Medical(Paris, France) said a study of its endovascular aneurysm repair (EVAR) system device showed patients had fewer endoleaks and needed fewer secondary interventions, and that their aneurysms shrank in volume and diameter. The company’s Kardiozis endovascular prosthesis uses thrombogenic fibers to embolize an abdominal aortic aneurism sac during a conventional EVAR procedure to prevent… […]
  • This cotton-based biofuel cell could power implanted medical devices
    Researchers at the Georgia Institute of Technology and Korea University have developed a glucose-powered biofuel cell that uses electrodes from cotton that could potentially power implantable medical devices. The fuel cell has twice as much power as traditional biofuel cells and could also be paired with batteries or super capacitors to create a hybrid power… […]
  • IEEE publishes safety standards draft for medtech interoperability
    The Institute of Electrical and Electronics Engineers (IEEE) Standards Association said it has published a draft set of standards intended to provide safe and secure medical device interoperability. IEEE 11073-20701-2018, also known as IEEE Approved Draft Standard for Service-Oriented Medical Device Exchange Architecture & Protocol Binding, completes the International Organization for Standardization (ISO)/IEEE 11073 family of standards… […]
  • FDA clears Safe Medical Design’s urethral catheter
    Safe Medical Design (San Francisco) said that FDA has cleared its Signal Catheter for commercialization in the United States. The 100% silicone foley catheter features a novel hub design allowing the catheter to reduce excessive balloon pressure in the event the catheter is improperly placed. Each year in the United States there are as many as 500,000… […]
  • These medtech companies raised the most VC in 2018
    Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively.… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS